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MBZ, but not ABZ, was found to significantly interact 
with several protein kinases including BCR–ABL and 
BRAF. Analysis of the diagnosis-specific activity of MBZ 
showed activity in 80 % of the colon cancer cell lines in 
the NCI 60 panel. Three additional colon cancer cell lines 
and three cell models with non-malignant phenotypes 
were subsequently tested, confirming selective colon 
cancer activity of MBZ.
Conclusion MBZ seemingly has repositioning potential 
for colorectal cancer therapy.
Keywords Repositioning · Colon cancer · Therapy · 
Benzimidazoles · Mebendazole
Introduction
In the past decades, target-based approaches with the aim 
to modulate specific diagnosis-related molecules and path-
ways have dominated the cancer drug discovery process 
and resulted in several successful novel therapies, best 
exemplified by the bcr–abl inhibitor imatinib for the treat-
ment for chronic myelocytic leukemia (CML) (Swinney 
and Anthony 2011). However, this approach is slow, has 
a high failure rate and it has become obvious that the rate 
of new drug approvals is decreasing (Hurle et al. 2013; 
Sukhai et al. 2011). Furthermore, the compounds that 
reach the market produce modest benefit in solid tumors 
(Hurle et al. 2013). Thus, new strategies for drug discov-
ery are needed. One such strategy is drug repositioning 
(or repurposing) in which a new indication for an existing 
drug is identified. In this approach, known on-patent, off-
patent, discontinued and withdrawn drugs with unrecog-
nized cancer activity can be rapidly advanced into clinical 
trials for this new indication as much or all of the required 
Abstract 
Purpose In the present study, we screened a compound 
library containing 1,600 clinically used compounds with 
the aim to identify compounds, which potentially could be 
repositioned for colon cancer therapy.
Methods  Two established colon cancer cell lines were 
tested using the fluorometric microculture cytotoxicity 
assay (FMCA). For compound comparison connectivity 
map (CMAP) analysis, NCI 60 data mining and protein 
kinase binding measurements were performed.
Results Sixty-eight compounds were defined as hits 
with activity in both of these cell lines (<40 % cell sur-
vival compared with control) at 10 μM drug concentra-
tion. Analysis of chemical similarity of the hit compounds 
revealed several distinct clusters, among them the antipar-
asitic benzimidazole group. Two of these compounds, 
mebendazole (MBZ) and albendazole (ABZ) are regis-
tered for human use. Data from the NCI 60 cell line panel 
revealed only modest correlation between MBZ and ABZ, 
indicating differences in mechanism of action. This was 
further supported when gene expression signatures were 
compared in the CMAP database; ABZ ranked very low 
when MBZ was used as the query signature. Furthermore, 
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documentation to support clinical trials can rely on pre-
viously published and readily available data (Hurle et al. 
2013).
Genomics-based target identification and screening 
using cell-free systems have been the dominating principle 
in cancer drug discovery during the recent decade (Mayr 
and Bojanic 2009). As an alternative to this approach, the 
use of phenotype-cell-based screening using human tumor 
cell lines may provide some distinct advantages (van 
Staveren et al. 2009). Cellular phenotype results from many 
interconnecting signaling and feedback pathways. Com-
pound screens based on isolated targets or cell components 
do not reflect this complexity. Indeed, it has recently been 
shown that the contribution of phenotypic screening to the 
discovery of first-in-class small molecule drugs exceeded 
that of target-based approaches (Swinney and Anthony 
2011). Furthermore, recent findings from large panels of 
cell lines indicate that they retain genomic features of the 
primary tumor and can recapitulate clinical findings with 
regard to response to targeted inhibitors (Sharma et al. 
2010).
In the present study, we used an annotated library con-
taining 1,600 compounds with documented clinical use 
for screening in colon cancer cell lines with the aim to 




Fig. 1  Screening for anticancer drug activity. The overall screening 
results are displayed and expressed as survival index. The symbols in 
green indicate the hit compounds (a). In b, the frequency of the major 
different pharmacological classes for the hit compounds is shown. Clus-
tering of compounds based on chemical structures using Vortex princi-
pal component analysis (PCA) is shown in c, and some of the clusters 
are highlighted including the benzimidazole group of compounds. The 
chemical structures of the hit benzimidazole compounds are shown in d




For primary screening, the colon cancer cell lines HCT 116 
and RKO, obtained from American Type Culture Collection 
(ATCC; Rockville, MD, USA), were cultured in McCoy’s 
5a medium supplemented with 10 % heat-inactivated fetal 
bovine serum, 2 mM l-glutamine, 100 μg/ml streptomycin 
and 100 U/ml penicillin (all from Sigma-Aldrich St. Louis, 
MO, USA).
The colon cancer cell lines HT29, HT-8 and SW626 and 
the normal phenotype non-malignant epithelial MCF 10A, 
renal RPTEC/TERT1 and hepatocyte NeHepLxHT cell 
lines were used for validation experiments. These cell lines 
were all obtained from ATCC and cultured according to the 
protocols provided by the supplier. All the cell lines were 
cultured at 37 °C in a humidified atmosphere containing 
5 % CO2.
Preparation of compounds for screening
The Pharmakon 1600 library (Microsource Inc, MO, USA) 
consists of 1,600 annotated compounds previously used 
in the clinical setting. The library was delivered in 36 
racks each containing 80 compounds at a concentration of 
10 mM dissolved in DMSO. For the primary screening, ali-
quots of the DMSO solutions were transferred to 384-well 
Labcyte source plates (Labcyte Inc, CA, USA) using a 
Biomek 2000 and stored at room temperature in contain-
ers under nitrogen atmosphere. These source plates were 
subsequently used to deliver 10 μM (final concentration) 
of each drug to 384-well screening plates using a acoustic 
dispensing Echo 550 instrument equipped with Labcytes 
Access robotics (Labcyte).
For dose–response studies, Labcyte source plates and 
the Echo dispenser were used in a similar manner to deliver 
different concentrations of each drug to destination plates 
using on board software protocols (Labcyte).
Measurement of cancer drug activity
The fluorometric microculture cytotoxicity assay (FMCA), 
described in detail previously (Lindhagen et al. 2008), was 
used for measurement of the cytotoxic effect of library 
compounds and the established standard drugs. The FMCA 
is based on measurement of fluorescence generated from 
hydrolysis of fluorescein diacetate (FDA) to fluores-
cein by cells with intact plasma membranes. Cells were 
seeded in 384-well plates using the pipetting robot Preci-
sion 2000 (Bio-Tek Instruments Inc, Winooski, VT) and 
cultured over night before drugs were added by the Echo 
550 system. The number of cells per well was 2,500–5,000 
adjusted individually for each cell line. In each plate, two 
columns without drugs served as controls and one column 
with medium only served as blank. Results are expressed as 
Fig. 2  In a, the activity of the 
benzimidazole hit compounds 
using the FMCA is shown. The 
results are presented as survival 
index. The correlation between 
MBZ and ABZ z scores in 
the NCI 60 cell line panel is 
shown in b. Pearson’s correla-
tion coefficient was 0.64. In c, 
CMAP results based on MBZ 
exposed MCF7 cells are shown. 
The CMAP score is a measure 
of similarity based on gene 
expression
z score
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survival index (SI), defined as fluorescence of experimental 
wells in per cent of unexposed control wells with blank val-
ues subtracted.
Gene expression analysis in the connectivity map
The drug-induced gene expression perturbations of MBZ 
and ABZ were studied using the connectivity map (CMAP) 
build 02 (www.broad.mit.edu/cmap) that contains genome-
wide expression data for 1,309 compounds (Lamb et al. 
2006). Since both ABZ and MBZ are present in the data-
base, the similarity in gene expression can be compared. 
The query was based on the genes (probes) with >twofold 
up- (31 probes) or down (70 probes)-regulation after treat-
ment with MBZ in MCF-7 cells (used since the most com-
plete data set is on MCF-7). CMAP score is a measure of 
correlation (−1 and +1) using Kolmogorov-Smirnov statis-
tics between the query signature and all other gene expres-
sion signatures in the CMAP database (Lamb et al. 2006).
Kinase assay
The binding affinities of ABZ and MBZ were tested at 10 μM 
in a high-throughput binding assay (KINOMEscan, Discoverx, 
CA, USA) against a panel of 97 kinases tagged with DNA 
(Davis et al. 2011). Compounds that bind the kinase active site 
and directly or indirectly prevent kinase binding to an immobi-
lized ligand will reduce the amount of kinase captured on solid 
support. Conversely, test molecules that do not bind the kinase 
have no effect on the amount of kinase captured on the solid 
support. Hits are identified by measuring the amount of kinase 
captured in test versus control samples by using a quantita-
tive PCR method that detects the associated DNA label (http:/
/www.discoverx.com/tools-resources/publications-references). 
Results are presented as percent of control (POC). Selectivity 
score (S-score) is a quantitative measure of compound selec-
tivity. S(35) is calculated as number of non-mutant kinases 
with POC <35/number of non-mutant kinases tested. Bind-
ing constants were determined with the same method using 
11-point threefold serial dilutions of the compound. Curves 
were fitted using a nonlinear least square fit with the Leven-
berg–Marquardt algorithm (Davis et al. 2011).
Data analysis and statistics
Screening data were exported to Vortex (Dotmatics Inc, 
UK) software for analysis. A SI of <40 % in both colon 
cancer cell lines was set as the criteria for qualifying as a 
hit compound. Structural similarity to other compounds in 
the library was calculated based on a structural fingerprint 
consisting of chemical fragments located within the com-
pound as computed by Vortex. Clustering of compounds 
based on these fingerprints was then performed within the 
Vortex program.
Concentration–response data of screening hits and 
standard agents were analyzed using the software Graph-
Pad Prism4 (GraphPad Software Inc., San Diego, CA, 
USA). Data were processed using nonlinear regression to 
a standard sigmoidal dose–response model to obtain IC50-
values (the drug concentration resulting in a SI of 50 %).
Analysis of data from the National Cancer Institute 
growth inhibitory screen in 60 cell lines (NCI 60 GI 50 
data) was performed with the help by the NCI Cellminer 
database (http://discover.nci.nih.gov/cellminer/). Z scores 
are determined for each experiment/cell line pair by the 
subtraction from its intensity by the experiment mean 
(across the 60 cell lines) and division by the standard devia-
tion of the experiment (across the 60 cell lines). The z score 
average was then calculated as the mean across all experi-
ments that passed quality control criteria. The z score will 
have a mean of zero and a standard deviation of one.
Results and discussion
The cytotoxic/antiproliferative activities in response to 
the 1,600 annotated compounds with documented clini-
cal history at a concentration of 10 μM in the colon can-
cer cell lines RKO and HCT116 are shown in Fig. 1a. 
Sixty-eight hits, as defined above, were retrieved (4.25 % 
hit rate). Among the hits retrieved, the highest frequency 
was obtained for known antineoplastic agents followed 
Table 1  Binding affinities for mebendazole for various kinases
a
 Selected kinases with percent control (POC) values at 10 μM are 
shown
b
 Values are the average of two determinations
Kinases POC (10 μM)a Kd (μM)b
ABL1(E255K) phosphorylated 0.3 0.078
ABL1(T315I) phosphorylated 4.8 0.170
ABL1 nonphosphorylated 2.4 0.550







Fig. 3  The binding affinities of ABZ and MBZ were tested at 10 μM 
in a high-throughput binding assay (KINOMEscan, Discoverx) 
against a panel of 97 kinases. In a, b, the treespot dendrogram for 
ABZ and MBZ are shown, respectively. The percent of control values 
<25 % for MBZ for selected cancer related kinases are shown in c
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Fig. 4  Analysis of NCI 60 data. The mean graph based on z scores 
for MBZ is shown in a. In (b), the frequency of positive z scores 
(sensitive cell lines) for all subpanels of the NCI 60 with more than 
4 members is displayed. In c, concentration-dependent effects of 
MBZ on cell survival in five colon cancer cell lines (HCT 116, RKO, 
HT29, HT-8 and SW626) and in three cell lines with non-malignant 
phenotypes (epithelial MCF 10A, renal RPTEC/TERT1 and hepato-
cyte NeHepLxHT) are shown. Survival was determined over 72 h 
using the FMCA assay. The results are expressed as percentage of the 
untreated control and presented as mean values ± standard error of 
the mean from three independent experiments
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by anti-parasitic drugs, anti-infectives and cardiovascu-
lar drugs (Fig. 1b). Clustering the compounds according 
to chemical structure using Vortex revealed clusters with 
similar chemical structure including anthracyclines, vinca 
alkaloids and cardiac glycosides (Fig. 1c). Interestingly, we 
also observed a distinct cluster containing the antihelmintic 
benzimidazole compounds albendazole (ABZ), mebenda-
zole (MBZ), oxibendazole and fenbendazole (Fig. 1d). This 
group of compounds were within 2 standard deviations of 
the library with respect to log P, molecular weight, hydro-
gen donors and hydrogen acceptor, and were thus well in 
agreement with the Lipinski’s rule of 5 criteria (not shown). 
Oxibendazole and MBZ showed the lowest SIs in the two 
cell lines screened closely followed by ABZ and fenbenda-
zole (Fig. 2a). From a repositioning perspective, MBZ and 
ABZ are registered pharmaceuticals for clinical use in 
humans, thus easily accessible for clinical testing, and were 
therefore prioritized for further analysis.
ABZ has previously demonstrated activity in several 
cancer types including colon cancer (Králová et al. 2013; 
Pourgholami et al. 2001, 2005). MBZ on the other hand 
has not previously been reported to be active in this dis-
ease and may have advantages both with respect to toxic-
ity and efficacy. Thus, ABZ appears to have a more severe 
toxicity profile, including neutropenia and anemia (http://
bioinformatics.charite.de/promiscuous/, von Eichborn et al. 
2011). In a clinical study of patients with advanced cancers, 
ABZ-induced neutropenia (Morris et al. 2001) and neutro-
penia was also the dose-limiting toxicity in a subsequent 
formal dose-escalating phase-I trial (Pourgholami et al. 
2010). ABZ has been reported to be redox active leading to 
strong reactive oxygen species (ROS) generation (Locatelli 
et al. 2004) potentially adding to the reported drug-induced 
toxicity. ROS generation could lead to several toxicological 
consequences as a result of oxidative injury to important 
biomolecules such as DNA, proteins and lipids (Kalinow-
ski and Richardson 2007). In contrast, MBZ, although 
belonging to the benzimidazole group of compounds, 
showed only a low and transient effect on ROS generation 
(Locatelli et al. 2004). This suggests that MBZ could be the 
first-choice drug since it causes only a mild oxidative stress 
and thus is expected to better tolerate in the clinical setting.
Also from the standpoint of efficacy, MBZ may have 
advantages as demonstrated in a study of preclinical glioma 
models (Bai et al. 2011). In this study, MBZ, but not ABZ, 
was able to significantly increase survival in two orthotopic 
mouse models of glioma (Bai et al. 2011). In this context, 
it is worth noting that ABZ and MBZ activity patterns show 
only moderate correlations in the NCI60 panel (Pearson’s 
correlation coefficient 0.64, Fig. 2b). Furthermore, when 
the ABZ- and MBZ-induced gene expression profiles were 
compared using the CMAP database, ABZ was only ranked 
number 222 using MBZ as the query signature (Fig. 2c). 
These results indicate differences in mechanism of action 
between ABZ and MBZ.
We subsequently tested the binding affinities of MBZ 
and ABZ at 10 µM against a panel of 97 kinases. Whereas 
no kinase binding was observed for ABZ, MBZ appeared 
to be a potent inhibitor of several kinases with high affinity 
(POC <22, Fig. 3). Binding constants (Kds) in response to 
MBZ were also determined for selected kinases (Table 1) 
Interestingly, MBZ showed strong activity with Kds in the 
nanomolar range against ABL kinases including the T315I 
gatekeeper binding site point mutation which remain a 
major clinical challenge in treatment for CML. Cells that 
harbor this mutation are insensitive to most of the clinically 
available ABL-targeted drugs. Furthermore, MBZ was also 
shown to potently bind to BRAF and especially to mutant 
BRAF(V600E), which is of clinical relevance in melanoma 
and colon cancer (Fig. 3; Table 1). In CMAP, the MBZ-
induced gene expression profile correlated strongly with 
nocodazole a well-known tubulin inhibitor with chemical 
structure similarity to MBZ. Also nocodazole has recently 
been shown to inhibit several protein kinases including 
Bcr–Abl (Park et al. 2012). These results thus suggest addi-
tional potential targets of importance for MBZ efficacy.
Analysis of the diagnosis-specific activity of MBZ using 
NCI 60 z score data revealed 80 % of the colon cancer cell 
lines to be sensitive, second only to the leukemia panel 
(Fig. 4a). The lung and renal cancer subpanels showed 
the lowest frequency of sensitive cell lines, 25 and 28 %, 
respectively (Fig. 4b). The average GI 50 over the panel 
was 0.46 μM.
Five colon cancer cell lines, including those used in the 
primary screen, and three cell lines with non-malignant 
phenotypes were subsequently tested for response to MBZ 
(Fig. 4c). All 5 colon cancer cell lines showed a MBZ IC50 
of <5 µM whereas the drug was largely inactive in the non-
malignant cell line models, thus indicating a potentially 
good therapeutic index in colon cancer (Fig. 4c). Indeed as 
a first indication of this possibility, a patient with refrac-
tory metastatic colon cancer was treated with MBZ at the 
standard anthelmintic dose of 100 mg twice daily. The 
patient experienced no subjective adverse effects at all from 
the drug and computerized tomography evaluation after six 
weeks of therapy showed near complete remission of the 
metastases in the lungs and lymph nodes and a good partial 
remission in the liver (case report accepted for publication 
in Acta Oncologica).
In conclusion, the overall results indicate that MBZ have 
repositioning potential for treatment of advanced colon 
cancer and clinical trials seem warranted.
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